Test kit for detecting concentration of cardiovascular disease-related biomarker and concentration detection method for detecting concentration of cardiovascular disease-related biomarker

Abstract

The present disclosure relates to a test kit for detecting a concentration of a cardiovascular disease-related biomarker including a group selected from the group consisting of a first aptamer, a second aptamer and a third aptamer. The first aptamer has binding specificity to an N-terminal pro-brain natriuretic peptide (NT-proBNP). The second aptamer has binding specificity to a cardiac Troponin I (cTnI). The third aptamer has binding specificity to a fibrinogen.

Description

RELATED APPLICATIONS[0001]This application claims priority to Taiwan Application Serial Number 108107497, filed Mar. 6, 2019, which is herein incorporated by reference.SEQUENCE LISTING[0002]The sequence listing submitted via EFS, in compliance with 37 CFR § 1.52(e)(5), is incorporated herein by reference. The sequence listing text file submitted via EFS contains the file “CP-4364-US_Sequence Listing”, created on Aug. 28, 2019, which is 3,207 bytes in size.BACKGROUNDTechnical Field[0003]The present disclosure relates to a test kit and a detection method thereof. More particularly, the present disclosure relates to a test kit for detecting a concentration of a cardiovascular disease-related biomarker including an aptamer that binds specifically to a cardiovascular disease-related biomarker and the concentration detection method thereof.Description of Related Art[0004]According to statistics released by the World Health Organization (WHO) in 2016, cardiovascular disease (CVD) is the to...

AI Technical Summary

Benefits of technology

The present patent describes a test kit for detecting the concentration of three biomarkers associated with cardiovascular disease: N-terminal pro-brain natriuretic peptide (NT-proBNP), cardiac Troponin I (cTnI), and fibrinogen. This test kit includes three specific aptamers that can bind to each biomarker and produce a detectable signal. By measuring the binding value of the sample with the test kit, the concentration of the biomarker can be accurately determined using a regression equation. This test kit provides a reliable and sensitive tool for detecting cardiovascular disease and monitoring its progression.

Problems solved by technology

There is a large amount of data suggesting the high risk of recurrence, morbidity, and mortality due to poor prognosis in cardiovascular disease, and many people are already at risk.

However, the instruments mentioned above are installed in specific institutions, and it is not possible to conduct regular inspection and monitoring of all patients due to the limited availability of these medical resources.

However, using conventional indicators, such as low-density cholesterol, triglycerides, body mass index (BMI), waistline, blood pressure, and the presence of diabetes or abnormal renal function to determine the risks of cardiovascular disease has its importance but lacks in efficacy.

However, antibodies are costly to produce and have low stability at varied temperature range; they require stricter storage conditions and are limited by the target epitopes in many cases.

Images